2023
Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial
Strober B, Zeichner J, Desai S, Cameron M, Cather J, Bruno M, Rubenstein D, Tallman A, Brown P. Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial. SKIN The Journal Of Cutaneous Medicine 2023, 7: s125. DOI: 10.25251/skin.7.supp.125.Peer-Reviewed Original Research
2021
POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Mease P, Lertratanakul A, Strober B, Tsuji S, Richette P, Lovan C, Feng D, Anderson J, Van den Bosch F. POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Annals Of The Rheumatic Diseases 2021, 80: 788-789. DOI: 10.1136/annrheumdis-2021-eular.564.Peer-Reviewed Original ResearchMinimal disease activityBiologic DMARDsOverall study populationInadequate responseAbbVie Inc.Boehringer IngelheimSpeakers bureauClinical trialsStudy populationEli LillyConsistent efficacyBristol-MyersFirst-line anti-TNF therapyDisease-modifying anti-rheumatic drugsSF-36 physical component summaryAnti-TNF therapyComprehensive disease controlPrior inadequate responseSubgroups of ptsThird-line therapyAnti-rheumatic drugsInvestigator's Global AssessmentSanofi-AventisPhysical component summaryConfidence intervals